How much does Decavatinib cost?

Deuterated colexitinib (decavatinib), as an innovative oral selective JAK1 inhibitor, has shown significant efficacy in the treatment of autoimmune diseases such as psoriasis (psoriasis) in recent years. With its domestic launch and inclusion in medical insurance, the financial burden on patients has been effectively alleviated. The current common specifications of deuterated colexitinib in China are 6mg*7 tablets, and the price is about more than 1,000 yuan. The coverage of medical insurance allows patients to obtain higher financial support during the treatment process, improving the accessibility of drugs and the continuity of treatment.

Compared with domestic prices, the price of the original deuterated colexitinib drug in the U.S. market is significantly higher. The U.S. version of deuterated colexitinib6mg*30 tablets is priced at about 50,000 yuan. The high price is mainly due to R&D investment, market monopoly during the patent protection period, and the complex medical and insurance systems in the United States. The high price undoubtedly puts greater financial pressure on patients and limits the medication options for some patients. In addition, the high drug prices in the United States also reflect the accumulation of costs in R&D, supervision, and marketing of original drugs.

In order to meet the medication needs of more patients and reduce the economic burden, countries such as Laos and Bangladesh have launched formally approved generic versions of deuterated colexitinib. The ingredients and efficacy of these generic drugs are basically the same as those of the original drugs, ensuring the effectiveness and safety of the treatment. The price of generic drugs with the specifications of 6mg*30 tablets has been significantly reduced. The latest selling price is only about 400 to 500 yuan, which has a clear price advantage compared with the original drugs. Affordable generic drugs provide patients with more choices, especially in areas with relatively limited medical resources.

Overall, the price of deuterated colexitinib varies greatly in different countries and regions, reflecting differences in medical policies, market environments and drug supervision in different regions. The domestic policy of including medical insurance has greatly reduced patients' medication pressure, while the high-priced original drugs from abroad, especially the United States, have placed a heavy burden on many patients. The emergence of generic drugs not only reduces the cost of treatment, but also promotes more patients to receive standardized treatment. When choosing deuterated colexitinib, patients should reasonably choose purchase channels based on their own financial situation and doctor's advice to ensure the quality and efficacy of the drug, and to ensure the safety and effectiveness of treatment.

Reference materials:https://go.drugbank.com/drugs/DB16650